Attovia extends biotech IPO streak Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T Wed Th F 5 August, 2026

One night, one room: the founders, scientists and investors behind the Endpoints 11, together in Boston this September. Reserve your spot now and save with the early bird rate.

presented by Why Amer­i­ca's med­i­cine be­came a na­tion­al se­cu­ri­ty ques­tion

SPOTLIGHT In Focus Novo vs. Lilly: Q2's cardiometabolic grudge match

news Novo Nordisk eyes bolt-on deals as pipeline disappointments pile up Attovia extends biotech IPO streak with $289M listing for three I&I drugs Lilly beats forecasts again as tirzepatide makes up nearly two-thirds of revenue Amgen culls early-stage obesity candidate, makes pipeline updates Gilead’s Yeztugo beats forecasts as HIV PrEP franchise exceeds $1B

Aug 19 1:00 pm ET From pilots to production: AI across R&D, safety, regulatory, and clinical sponsored by IBM Aug 27 12:00 pm ET Same molecule, different paths: Where value goes in cross-border dealmaking in a new era sponsored by PharmCube Sep 03 11:00 am ET How leading pharma organizations are putting AI agents to work sponsored by Medable

Scientist, Drug Discovery Data for AI/ML D. E. Shaw Research New York, NY, USA Machine Learning Researchers and Engineers D. E. Shaw Research New York, NY, USA Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

The China biotech story is moving fast. On Aug. 6, Endpoints hosts debate-style panels on how China's rise is forcing biotech to rethink innovation, live in Boston. Space is limited. Reserve your spot now.

ENDPOINTS PHARMA Merck plans a sac-TMT combo trial with Keytruda as patent cliff looms •  Merck's anti-TL1A antibody scores a win in hidradenitis suppurativa, fails in a rare lung disease Pfizer keeps cutting, eliminating costs and programs as pipeline delivers mixed results •  Pfizer has already made its biggest deals, Bourla says The China Debate: Biotech deserves a deeper discussion — see you in Boston

in case you missed it 1. Post-Hoc Live: Who wants an AstraZeneca-Bristol Myers megadeal?